Document is current
Any future updates will be listed below
-
Authors
Muto, Tomohiro https://orcid.org/0009-0005-9403-9743
Ito, Go https://orcid.org/0009-0004-7488-0335
Katsuda, Hiromune https://orcid.org/0009-0006-4128-534X
Hiraguri, Yui
Fujii, Satoru https://orcid.org/0009-0003-2220-0484
Yamamoto, Kurara https://orcid.org/0000-0002-5272-6458
Bernardes, Joana P. https://orcid.org/0009-0005-1429-8412
Hinrichsen, Finn https://orcid.org/0009-0002-6952-7348
Uchida, Hitoshi https://orcid.org/0009-0006-1474-773X
Nemoto, Yasuhiro https://orcid.org/0009-0009-7619-2356
Kinoshita, Mayumi
Oshina, Eri https://orcid.org/0000-0001-5289-1245
Yamamoto, Kouhei
Hibiya, Shuji https://orcid.org/0000-0001-8823-7755
Nagata, Sayaka
Schuran, Fenja
Yui, Shiro https://orcid.org/0000-0003-4268-647X
Pelczar, Penelope
Huber, Samuel https://orcid.org/0000-0001-9325-8227
Schreiber, Stefan https://orcid.org/0000-0003-2254-7771
Rosenstiel, Philip https://orcid.org/0000-0002-9692-8828
Watanabe, Mamoru https://orcid.org/0000-0002-5475-9544
Okamoto, Ryuichi https://orcid.org/0000-0002-7047-571X
- License Information
-
More Information
Article History
Received: 19 December 2024
Accepted: 13 March 2026
First Online: 28 March 2026
Competing interests
: S.S. reports receiving consulting fees, speaker fees, and support for attending meetings and/or travel from AbbVie, Alfasigma, Arena, Biogen, Bristol Myers Squibb, Celltrion, Lilly, Fresenius, Gilead, I-Mab, Janssen, Pfizer, Protagonist Therapeutics, ProventionBio, Takeda, and Ventyx, and from Celgene, Falk, Ferring, and Galapagos, outside the submitted work. G.I. and M.W. report that this study was partially supported by research funding from EA Pharma Co., Ltd. All other authors declare no competing interests.
: For natural language processing and language editing, we utilized ChatGPT and Copilot.
